Thursday's top gainers include Veru, following a Novo Nordisk collaboration; Health Catalyst, following a divestment of its revenue workflow and analytics software business; Absci, ahead of clinical trial readouts; and Alvotech, which is taking another shot at FDA approval for its biosimilars, among others.